attyloid is a biotech spin-off built on strong scientific expertise in the field of protein misfolding and aggregation. We have developed an ultra-sensitive quantitative technology platform with value-adding potential as biomarker of CNS diseases and drug effect assaying, development and QC of biologicals, and counting of viral particles.
sFIDA is able to be utilized as a unique biomarker in CNS drug development enabling patient stratification and quantitative measures of target engagement and drug effect. In QC of biologicals and viral particle analysis, sFIDA bridges the present analytical gap in the subvisible range (0.1-10 microns). MORE
attyloid draws on a strong team of founders with expertise in Life Science, Health Care and Corporate Development.
Dr. Oliver Bannach
Dr. Andreas Kulawik
Dr. Christian Zafiu
Prof. em. Dr. Dr. h.c. Detlev Riesner
Prof. Dr. Dieter Willbold
Supervisory Board Chairman
Get in Touch
Fon: +49 (0) 211 81-10377